Patency Capsule Tolerability in School-Aged Children

Tokuhara, Daisuke; Watanabe, Kenji; Cho, Yuki; Shintaku, Haruo

doi:10.1159/000477579

Cited by 10 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To assess the small intestinal patency and predict the retention, a dissolving Pill Cam patency capsule was released in 2012. Its tolerability in children has not been guaranteed yet though the safety is confirmed in adults [3]. The limitation of CE is its inability to obtain biopsies and provide endoscopic treatments.…”

Section: Utility Of Ce In Ogibmentioning

confidence: 99%

Clinical Utility of Capsule Endoscopy and Double-Balloon Enteroscopy in the Management of Obscure Gastrointestinal Bleeding

et al. 2018

View full text Add to dashboard Cite

Background: Obscure gastrointestinal bleeding (OGIB) is a common but embarrassing problem for gastroenterologists. Most bleeding lesions associated with OGIB are present in the small intestine and sometimes cannot be identified due to the difficulty associated with physical accessibility. Capsule endoscopy (CE) and double-balloon enteroscopy (DBE) have enabled in the process of diagnosing and have evolved to become approaches to treating OGIB. Summary: CE is a minimally invasive procedure and has a high diagnostic yield in patients with OGIB. DBE offers additional advantage of biopsy collection for pathological diagnosis and therapeutic intervention, but it should be noted that it sometimes causes severe adverse events such as acute pancreatitis, intestinal bleeding, and intestinal perforation. CE should be performed early in the workup course of OGIB. Positive CE findings enhance the diagnostic yield of subsequent DBE, and the effective therapeutic intervention improves the clinical outcomes of OGIB patients. On the contrary, there are no clear guidelines for further investigation of patients with negative CE findings at the present. Although patients in stable general condition may only require follow-up, repeated CE is useful to detect positive findings in patients with evidence of sustained bleeding and progressing anemia. We have revealed that repeated CE has higher positive finding rate than DBE in OGIB patients with negative CE findings in a preliminary study. Key Messages: CE and DBE have complementary roles in the management of OGIB, and the precise timing and proper sequence may be important for the approach to treating OGIB.

show abstract

Section: Utility Of Ce In Ogibmentioning

confidence: 99%

Clinical Utility of Capsule Endoscopy and Double-Balloon Enteroscopy in the Management of Obscure Gastrointestinal Bleeding

et al. 2018

View full text Add to dashboard Cite

show abstract

“…We observed no issues confirming functional patency using the tag-less PPC and expect that the Agile TM Patency Capsule will be replaced with the PPC in the future globally. Previous published studies of the PPC have basically investigated its usefulness for confirming patency at 30-33 h after ingestion [11][12][13][14][15][16][17]. As far as we know, our study is the only study that has investigated the clinical course from 30 to 72 h after ingestion of the tagless PPC.…”

Section: Discussionmentioning

confidence: 96%

A Prospective Study Evaluating the Clinical Utility of the Tag-Less Patency Capsule with Extended Time for Confirming Functional Patency

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background: Patency confirmation is useful for avoiding the retention of capsule endoscopy (CE). We first evaluated the clinical utility of the tag-less PillCam^TM Patency Capsule (PPC) for up to 72 h after ingestion prospectively. Methods: Excretion of an intact capsule or intact body within 72 h, or positive PPC image in the colon or negative PPC image by abdominal X-ray at 30 h was defined as confirmed functional patency. In patients with unconfirmed functional patency, balloon-assisted enteroscopy was performed to evaluate the reason. Results: Functional patency was confirmed in 44 of 57 patients. Patency was confirmed in 38 patients (66.7%) at 30 h. In 6 of 19 patients (31.6%) in whom patency was not confirmed at 30 h, patency was confirmed within 72 h and no capsule retention (CR) occurred. The rate of pan-enteroscopy did not differ between patients whose patency was confirmed at 30 h and those whose patency was confirmed within 72 h. Excretion time of the PPC significantly correlated with that of the capsule (r = 0.650). Severe adhesions (>5 cm) interfered with PPC passage in 2 patients, despite the absence of critical stricture. The rate of no CR in patients with functional patency confirmed by prior PPC was 97.7%. Misjudgment of the location of the PPC is a risk for CR. Conclusions: Extending the time to confirm functional patency to 72 h may be acceptable and increase the possibility to perform CE safely in whom CE can perform intrinsically. University Hospital Medical Information Network registration No: 000002564.

show abstract

“…To investigate the lesion responsible for the patient's protein‐losing enteropathy, small bowel capsule endoscopy (SBCE) was planned. To exclude potential retention of the SBCE capsule, intestinal patency was examined by using a dissolvable patency capsule, as previously described 1 .…”

Section: Figmentioning

confidence: 99%

Symptomatic esophageal retention of a patency capsule due to extraesophageal compression from pulmonary artery stent grafts

Cho¹,

Tokuhara²

2021

Pediatrics International

Self Cite

View full text Add to dashboard Cite

Patency Capsule Tolerability in School-Aged Children

Cited by 10 publications

References 18 publications

Clinical Utility of Capsule Endoscopy and Double-Balloon Enteroscopy in the Management of Obscure Gastrointestinal Bleeding

Clinical Utility of Capsule Endoscopy and Double-Balloon Enteroscopy in the Management of Obscure Gastrointestinal Bleeding

A Prospective Study Evaluating the Clinical Utility of the Tag-Less Patency Capsule with Extended Time for Confirming Functional Patency

Symptomatic esophageal retention of a patency capsule due to extraesophageal compression from pulmonary artery stent grafts

Contact Info

Product

Resources

About